Abstract
Discussion and SummaryDromoran® passes without difficulty across the placental barrier and produces a decrease in the rate of respiratory movements of the fetuses. This passage across the placental barrier might be expected in view of the general principle stated by Needham(8) that the placental barrier is freely passed by practically all substances of low molecular weight. Thus in obstetrical analgesia one can assume that the agent will pass the placental barrier and the best analgesic will be one which will have high analgesic potency in the mother and a minimal effect on fetal respiration activity. The final evaluation of an analgesic must therefore be made under clinical conditions where the analgesic property can be evaluated in the patient. The doses of Dromoran® used in these experiments were much higher than would be used for human patients and there is no doubt but what satisfactory analgesia in humans can be obtained with lower doses. The question of whether these doses depress the respiratory f...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.